BioNano Genomics, Inc. (NASDAQ:BNGO) was founded in January 2003 under the name BioNanomatrix LLC, then changed its name to BioNanomatrix Inc. in August 2007, and was renamed BioNano Genomics, Inc. in October 2011, and is headquartered in San Diego, California, USA, with 77 full-time employees, is a life science instrument company focusing on the field of genome analysis.
BioNano Genomics, Inc. (BNGO):
BioNano Genomics, Inc. develops and markets the Saphyr system, which is an ultra-sensitive and ultra-specific structural variation detection platform that enables researchers and clinicians to accelerate research on new diagnostic and therapeutic targets, and simplify the study of chromosomal changes. This is called cytogenetics. The company’s Saphyr system includes instruments, chip consumables, reagents and a set of data analysis tools.
Structural variation refers to the large-scale structural difference between the genomic DNA of one individual and the genomic DNA of another individual. Each structural variation involves rearrangements involving hundreds to tens of millions of DNA base pairs. Structural variations can be hereditary or spontaneous, and many lead to inherited diseases and diseases. Before BioNano Genomics commercially launched the Saphyr system in February 2017, there was no product on the market that could effectively detect structural variation in a comprehensive, cost- and time-sensitive manner.
BioNano Genomics has established partnerships with authorities in the field of genomics research and clinical applications, including rare diseases and oncology. The company has installed 90 sets of Saphyr systems, and its customers include some of the most famous clinical, translational, and basic research in the world , Academic and government agencies, and leading pharmaceutical and diagnostic companies. Including: Children’s National Health System, DuPont Pioneer, Garvan Institute of Medical Research, Genentech, Icahn School of Medicine at Mount Sinai Kan School of Medicine), McDonnell Genome Institute at Washington University, National Institutes of Health, Pennsylvania State University and Salk Institute for Biological Studies Erke Institute of Biology).
In 2017, BioNano Genomics’ revenue was US$9.5 million, an increase of approximately 40% over the previous year, while the company’s revenue in the first half of 2018 was US$5.2 million, an increase of approximately 32% over the same period last year. From January 1, 2016 to June 30, 2018, the cumulative income of the customers listed above were 0.5M, 0.5M, $0.3M, $0.3M, $0.1M, $0.4M, $0.1M, $ 0.3M, and 0.1M USD.
BioNano Genomics, Inc. (BNGO) investment:
BioNano Genomics, Inc. (NASDAQ:BNGO) submitted its IPO prospectus on 6/28/2018, and listed on Nasdaq on 8/6/2018 with an issue price of US$6.125. It issued 3.36 million shares and raised US$20.58 million. Underwriting by Roth Capital Partners.